Press coverage about Pacific Biosciences of California (NASDAQ:PACB) has been trending positive recently, according to Accern. The research firm identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Pacific Biosciences of California earned a news sentiment score of 0.38 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 47.3004934548277 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the media stories that may have impacted Accern Sentiment Analysis’s rankings:
- Pacific Bio (PACB) Receives U.S. Patent for Concatemer Sequencing (streetinsider.com)
- Pacific Biosciences Announces Issuance of U.S. Patent for Concatemer Sequencing (finance.yahoo.com)
- Short Interest in Pacific Biosciences of California (PACB) Decreases By 10.8% (americanbankingnews.com)
- Analyzing Cogentix Medical (CGNT) and Pacific Biosciences of California (PACB) (americanbankingnews.com)
- Pacific Biosciences of California, Inc. (PACB) Stock Unusual Activity – Wall Street Morning (wallstreetmorning.com)
Pacific Biosciences of California (NASDAQ PACB) opened at $2.79 on Wednesday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.74 and a current ratio of 3.55. The company has a market capitalization of $356.79, a P/E ratio of -3.13 and a beta of 1.54. Pacific Biosciences of California has a twelve month low of $2.21 and a twelve month high of $5.70.
PACB has been the subject of several recent research reports. BidaskClub upgraded Pacific Biosciences of California from a “strong sell” rating to a “sell” rating in a research report on Thursday, December 21st. Zacks Investment Research downgraded Pacific Biosciences of California from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. Three analysts have rated the stock with a sell rating, two have issued a hold rating and one has issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $6.27.
TRADEMARK VIOLATION WARNING: This piece of content was first reported by BBNS and is the sole property of of BBNS. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://baseballnewssource.com/2018/03/14/pacific-biosciences-of-california-pacb-earns-news-impact-score-of-0-38/2028074.html.
About Pacific Biosciences of California
Pacific Biosciences of California, Inc designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company is engaged in the development, manufacturing and marketing of an integrated platform for genetic analysis. Its Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes.
Receive News & Ratings for Pacific Biosciences of California Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California and related companies with MarketBeat.com's FREE daily email newsletter.